Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(48)
Published: Sept. 6, 2023
Abstract
Nanotechnology
is
revolutionizing
cancer
therapy,
and
catalyzes
the
emerging
of
ion‐involved
cancer‐therapeutic
modality,
which
unfortunately
suffers
from
undesirable
nanocarriers
for
efficient
intracellular
ion
delivery.
To
radically
extricate
this
critical
issue,
glutathione
(GSH)‐responsive
organosilica
network
employed
to
lock
liquid
drops
at
nanoscale
via
a
general
bottom‐up
strategy
achieve
systemic
delivery
“ion
drugs”.
In
work,
sulfate
radical
generation
donor
(Na
2
S
O
8
),
as
paradigm
drug”,
entrapped
into
nanoparticle
efficiently
delivering
tumor
region.
After
further
surface
engineering
with
pH‐responsive
tannic
acid‐Fe
2+
framework,
these
nanoparticles
tumor‐microenvironmental
pH/GSH‐dual
responsive
release
(Fe
/Na
+
/S
2−
)
after
reaching
sites,
where
Fe
triggers
generate
toxic
•SO
4
−
•OH,
effectively
executing
cell
ferroptosis
,
reactive
oxygen
species—ROS)
pyroptosis
ROS).
Such
tumor‐responsive/specific
nanoplatform
highly
instructive
ion‐mediated
nanomedicine
disease
treatment.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(12), P. 11492 - 11506
Published: June 7, 2023
Ferroptosis
therapy
(FT)
efficacy
of
tumors
suffers
from
a
relatively
low
concentration
Fenton
agents,
limited
hydrogen
peroxide
(H2O2)
content,
and
insufficient
acidity
in
the
tumor
environment
(TME),
which
are
unfavorable
for
reactive
oxygen
species
(ROS)
generation
based
on
or
Fenton-like
reactions.
The
glutathione
(GSH)
overexpression
TME
can
scavenge
ROS
abate
FT
performance.
In
this
study,
strategy
storm
specifically
initiated
by
our
developed
nanoplatforms
(TAF-HMON-CuP@PPDG)
is
proposed
high-performance
tumors.
GSH
initiates
HMON
degradation,
resulting
tamoxifen
(TAF)
copper
(CuP)
release
TAF3-HMON-CuP3@PPDG.
released
TAF
leads
to
enhanced
acidification
within
cells,
reacts
with
CuP
producing
Cu2+
H2O2.
reaction
between
H2O2
generates
Cu+,
that
Cu+
Cu2+,
forming
cyclic
catalysis
effect.
generate
GSSG.
increased
accelerate
consumption
decreases
peroxidase
4
(GPX4)
expression.
All
above
reactions
cells
FT,
demonstrated
cancer
tumor-bearing
mice.
ACS Nano,
Journal Year:
2022,
Volume and Issue:
16(9), P. 13513 - 13553
Published: Sept. 1, 2022
Prodrugs
are
chemically
modified
drug
molecules
that
inactive
before
administration.
After
administration,
they
converted
in
situ
to
parent
drugs
and
induce
the
mechanism
of
action.
The
development
prodrugs
has
upgraded
conventional
treatments
terms
bioavailability,
targeting,
reduced
side
effects.
Especially
cancer
therapy,
application
achieved
substantial
therapeutic
From
serendipitous
discovery
early
stage
functional
design
with
pertinence
nowadays,
importance
is
self-evident.
At
present,
studying
stimuli-responsive
activation
mechanisms,
regulating
stimuli
intensity
vivo,
designing
nanoscale
prodrug
formulations
major
strategies
promote
prodrugs.
In
this
review,
we
provide
an
outlook
recent
cutting-edge
studies
on
nanosystems
from
these
three
aspects.
We
also
discuss
prospects
challenges
future
such
Advanced Materials,
Journal Year:
2022,
Volume and Issue:
35(21)
Published: Dec. 16, 2022
Radiotherapy
(RT)
uses
ionizing
radiation
to
eradicate
localized
tumors
and,
in
rare
cases,
control
outside
of
the
irradiated
fields
via
stimulating
an
antitumor
immune
response
(abscopal
effect).
However,
therapeutic
effect
RT
is
often
limited
by
inherent
physiological
barriers
tumor
microenvironment
(TME),
such
as
hypoxia,
abnormal
vasculature,
dense
extracellular
matrix
(ECM),
and
immunosuppressive
TME.
Thus,
it
critical
develop
new
strategies
that
can
remodel
TME
overcome
radio-resistance
suppression.
In
past
decade,
high-Z-element
nanoparticles
have
been
developed
increase
radiotherapeutic
indices
reducing
X-ray
doses
side
effects
normal
tissues
enhance
abscopal
activating
elicit
systemic
immunity.
this
review,
principles
radiosensitization,
mechanisms
suppression,
use
various
sensitize
TMEs
for
enhanced
efficacy
are
discussed.
The
challenges
clinical
translation
multifunctional
TME-remodeling
nanoradiosensitizers
also
highlighted.
Advanced Materials,
Journal Year:
2022,
Volume and Issue:
34(15)
Published: Feb. 18, 2022
Deleterious
effects
to
normal
tissues
and
short
biological
half-life
of
sonosensitizers
limit
the
applications
sonodynamic
therapy
(SDT).
Herein,
a
new
sonosensitizer
(Cu(II)NS)
is
synthesized
that
consists
porphyrins,
chelated
Cu
Cancers,
Journal Year:
2022,
Volume and Issue:
14(19), P. 4568 - 4568
Published: Sept. 21, 2022
Reprogramming
of
glucose
metabolism
provides
sufficient
energy
and
raw
materials
for
the
proliferation,
metastasis,
immune
escape
cancer
cells,
which
is
enabled
by
metabolism-related
enzymes
that
are
abundantly
expressed
in
a
broad
range
cancers.
Therefore,
targeting
has
emerged
as
promising
strategy
anticancer
drug
development.
Although
several
modulators
have
been
approved
treatment
recent
years,
some
limitations
exist,
such
short
half-life,
poor
solubility,
numerous
adverse
effects.
With
rapid
development
medicinal
chemicals,
more
advanced
effective
enzyme-targeted
drugs
developed.
Additionally,
studies
found
natural
products
can
suppress
progression
regulating
enzymes.
In
this
review,
we
summarize
mechanisms
underlying
reprogramming
present
could
serve
therapeutic
targets.
addition,
systematically
review
existing
enzymes,
including
small-molecule
products.
Finally,
opportunities
challenges
also
discussed.
conclusion,
combining
with
conventional
may
be
strategy.
Advanced Functional Materials,
Journal Year:
2023,
Volume and Issue:
33(16)
Published: Jan. 25, 2023
Abstract
Induction
of
immunogenic
cell
death
(ICD)
in
tumor
combined
with
immune
checkpoint
blockade
(ICB)
therapy
is
widely
developed
to
improve
the
efficacy
cancer
immunotherapy.
However,
current
ICD
induced
based
on
apoptosis,
i.e.,
often
restricted
immunogenicity
owing
inflammatory
quenching
that
occurs
early
apoptosis.
Recently,
pyroptosis
demonstrated
be
a
more
efficient
form,
pyroptosis.
The
contents
released
during
can
powerfully
activate
immunogenicity.
Herein,
first,
it
lower
doses
epigenetic
drug
decitabine
increase
GSDME
expression
prostate
(PCa)
RM‐1
cells
and
successfully
induce
an
apoptosis‐pyroptosis
transition
after
photodynamic
(PDT).
Subsequently,
microenvironment
dual‐responsive
nano‐drug
equipped
PD‐L1
blocking
peptide
(TSD@LSN‐D)
for
self‐synergistic
poorly
PCa
model
confirm
powerful
antitumor
response
evoked
by
TSD@LSN‐D
not
only
effectively
inhibit
primary
but
also
form
long‐term
memory
prevent
recurrence
metastasis.
To
best
authors’
knowledge,
this
work
presents
first
concept
promotes
apoptosis–pyroptosis
PDT
through
modulation.
Furthermore,
combination
ICB
opens
new
platform
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(12), P. 11537 - 11556
Published: June 5, 2023
Ferroptosis
activation
has
been
considered
a
mighty
weapon
for
cancer
treatment,
and
growing
attention
is
being
paid
to
reinforcing
tumor
cells'
sensitivity
ferroptosis.
However,
the
existence
of
certain
ferroptosis
resistance
mechanisms,
especially
abnormal
metabolism
cells,
long
underestimated.
We
propose
an
enhanced
ferroptosis-activating
pattern
via
regulating
glycometabolism
construct
nanoplatform
named
PMVL,
which
composed
lonidamine
(LND)-loaded
tannic
acid
coordinated
vanadium
oxides
with
camouflage
PD-L1
inhibiting
peptide-modified
cell
membrane.
This
work
reveals
that
mixed
valence
(VIV
VV)
in
PMVL
triggers
due
self-cyclic
alteration
V,
process
generates
•OH
lipid
peroxide
accumulation
→
depletes
glutathione
(GSH)
peroxidase
(GPX4)
deactivation
(VV
VIV).
Notably,
LND
strengthens
by
dual
suppression
glycolysis
(decreasing
ATP
supply)
pentose
phosphate
pathway
NADPH
production),
causing
anabatic
GSH
consumption.
Besides,
inhibited
less
intracellular
lactic
alleviates
acidity
microenvironment,
preventing
immunosuppressive
M2
macrophage
polarization.
In
vitro
vivo
data
demonstrate
glycometabolism-intervention-enhanced
boosted
immunity
activation,
potentially
providing
opportunities
possibilities
synergetic
therapy.
